SynteractHCR Proves Industry Expertise Through Conference And Webinar Education

Focus On Clinical Research Developments and Innovations

Executives from SynteractHCR, a full-service, international contract research organization (CRO), will participate in several speaking engagements and presentations this fall: an FDANews webinar on September 7, the Outsourcing Clinical Trials New England conference on September 7-8, the FierceBiotech Drug Development Forum on September 19-21, and the Disruptive Innovations US, better known as DPharm, conference on September 20-21. Each event brings together thought leaders in the clinical research industry to understand major changes and discuss best practices.

Dr. Martine Dehlinger-Kremer, Global Vice President, Medical & Regulatory Affairs for SynteractHCR and the chair of the pediatric working group for EUCROF, will discuss latest compliance developments and how they affect pediatric research requirements for both the FDA and EMA in her webinar entitled “Pediatric Clinical Trials Regulation: Latest FDA and International Compliance Developments”. The online-accessible session runs from 1:30-3:00 p.m. EDT on Sept. 7th. Registration details are available at this link: http://www.fdanews.com/pediatricctreg

At OCT New England, SynteractHCR Director of Regulatory Affairs Dr. Ludwig Baumann will present “The New EU Clinical Trials Regulation: The Impact It Will Have for US Sponsors Running Global Trials” from 10:00-10:30 a.m. EDT on day one of the event, September 7. In his presentation, Dr. Baumann will address important differences between the EMA’s and FDA’s expectations, among other key aspects.

Vice President, Strategic Development Etienne Drouet will present at the FierceBiotech Drug Development Forum on the “Partnerships in Immuno-Oncology” panel from 10:00-10:50 a.m. EDT on Tuesday, September 20. This discussion involves cancer immunotherapies, a growing trend in clinical research, and how the market surrounding these drugs will evolve in coming years.

Finally, SynteractHCR Project Director Cheryl Johnson will speak on the “Innovative Sources and Solutions” track of the “Innovation in Problem Solving” segment of DPharm, September 20. Here, Johnson will present a problem within clinical research and offer SynteractHCR’s process for providing a solution, with the goal of inspiring collaboration between different sides of clinical research.

About SynteractHCR
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.